Revolution Medicines’ daraxonrasib delivered a substantial survival benefit in a phase 3 trial for advanced pancreatic ductal adenocarcinoma, doubling median overall survival versus chemotherapy. Results from RASolute 302 were presented at ASCO 2026 and published in the New England Journal of Medicine. In the 500-patient study, daraxonrasib-treated patients lived a median 13.2 months compared with 6.7 months on investigator-choice chemotherapy. The drug also extended time to disease worsening, with progression-free dynamics favoring daraxonrasib. Clinically, the trial targets a pathway alterations found across the majority of pancreatic cancers, addressing a long-standing limitation of precision oncology in PDAC where options have historically been scarce. The dataset also supports continued interest in pan-RAS strategies as a route to broader pathway disruption. For the field, the readout is likely to increase scrutiny of next-step combinations and biomarker alignment given the high unmet need and limited responsiveness to established modalities in pancreatic cancer.